|
FDA sagt "Nein"
endpts.com/...da-shows-another-testosterone-therapy-the-door/
LPCN 1144
http://ir.lipocine.com/2019-01-17-Lipocines-NASH-Therapy-Candidate-Achieves-Meaningful-Liver-Fat-Reduction-Based-on-Interim-Results
Allerdings gibt es Kritik am Studiendesign:
"I could conduct another webinar on clinical trial red flags based solely on todays LPCN liver fat study press release. Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs, etc etc. "
https://twitter.com/adamfeuerstein/status/1085877664991178753
LPCN 1144
wieder Kritik von AF:
"Not that anyone trading cares, but today’s LPCN iver fat (NASH? NAFLD? Something else?) data are worse than the data previously disclosed in January. Also, wow, so many changes to endpoint definitions. Carry on…."
twitter.com/adamfeuerstein/status/1105446714276761600
FDA verweigert TLANDO zum dritten Mal die Zulassung
endpts.com/...ir-oral-testosterone-drug-snubbed-again-by-fda/
6 Mio. $ Offering
Was für schlechtes Timing vom Management. Finger weg!
ir.lipocine.com/...blic-Offering-Of-Common-Stock-And-Warrants
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 46 | Lipocine Inc | iwanooze | Vassago | 17.05.23 10:59 | |
6 | Lipocine im Aufwind | Tiger | Tiger | 09.12.22 12:44 |